Barclays Issues Positive Forecast for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its price target lifted by stock analysts at Barclays from $230.00 to $255.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the conglomerate’s stock. Barclays‘s target price indicates a potential upside of 17.57% from the stock’s current price.

A number of other analysts also recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $240.00 target price on shares of Danaher in a research report on Wednesday, July 22nd. Piper Sandler initiated coverage on shares of Danaher in a research note on Thursday, June 11th. They set a “neutral” rating and a $200.00 price objective on the stock. UBS Group assumed coverage on shares of Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective on the stock. Evercore reaffirmed an “outperform” rating and set a $230.00 target price on shares of Danaher in a research note on Monday, July 6th. Finally, Royal Bank Of Canada lifted their target price on shares of Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $235.23.

Danaher Stock Up 0.6%

Shares of NYSE DHR traded up $1.29 during mid-day trading on Wednesday, hitting $216.90. 426,304 shares of the stock traded hands, compared to its average volume of 4,439,927. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a market cap of $152.48 billion, a price-to-earnings ratio of 38.37, a PEG ratio of 2.75 and a beta of 0.76. The stock has a fifty day moving average price of $210.01 and a 200-day moving average price of $194.05.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.77 earnings per share. Research analysts anticipate that Danaher will post 8.53 EPS for the current year.

Institutional Investors Weigh In On Danaher

A number of institutional investors have recently made changes to their positions in DHR. Congress Asset Management Co. purchased a new position in Danaher in the 3rd quarter worth approximately $3,582,000. Moody National Bank Trust Division boosted its stake in Danaher by 14.5% during the 3rd quarter. Moody National Bank Trust Division now owns 7,993 shares of the conglomerate’s stock valued at $1,771,000 after purchasing an additional 1,015 shares during the last quarter. RVW Wealth LLC purchased a new stake in Danaher during the 3rd quarter valued at $4,118,000. Colton Groome Financial Advisors LLC bought a new stake in shares of Danaher in the 3rd quarter worth $592,000. Finally, Ables Iannone Moore & Associates Inc. purchased a new position in shares of Danaher in the third quarter worth $1,853,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.